[Platelet anti-aggregants in the prevention of disseminated intravascular coagulation in severe burns].
Two groups of patients with burns involving from 40-70% of the body surface have been examined. One group of 34 patients was not treated with antiaggregating therapy, and one of 28 was treated with platelet antiaggregating therapy from the first day of admission. It was noted that this treatment has a favourable influence on burn shock by means of a mechanism which impedes the onset of D.I.C.
D001241:Aspirin / Q000627:therapeutic use; D002056:Burns / Q000150:complications* / Q000188:drug therapy; D004176:Dipyridamole / Q000627:therapeutic use; D004211:Disseminated Intravascular Coagulation / Q000517:prevention & control*; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects*; D011517:Prothrombin Time
D005338:Fibrin Fibrinogen Degradation Products; D004176:Dipyridamole; D001241:Aspirin
Gli antiaggreganti piastrinici nella profilassi della C.I.D. nei grandi ustionati.